The presence of a BRAF p.V600E mutation was associated with poorer survival regardless of tumor site or sex but was most strongly associated with DS-survival for those with rectal tumors (HR 4.39, 95% CI 2.57–7.49, P = 5.94 × 10− 08) and particularly for women with rectal tumors (HR 8.27, 95% CI 4.38–15.61, P = 7.34 × 10− 11). This evidence concerns the gene BRAF and rectal neoplasm.